Venous Thrombosis
134
3
6
92
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
34 trials with published results (25%)
Research Maturity
92 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.7%
9 terminated out of 134 trials
91.1%
+4.5% vs benchmark
31%
41 trials in Phase 3/4
37%
34 of 92 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 92 completed trials
Clinical Trials (134)
The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry
A Study of the IJV or the SCV Approach for Ultrasound-guided Implantation of TIVAD
A Registry of the FLOWRUNNER Aspiration System for Patients With Symptomatic Venous Thrombosis
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
Collection of the Thrombo-VaxCov Cohort
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Epidemiology of Venous Thrombosis and Pulmonary Embolism
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Diagnostic Validity of [18F]GP1 PET for Diagnosing Acute Deep Vein Thrombosis
JETi Lower Extremity Venous Thrombosis
Evaluation of the Duration of Therapy for Thrombosis in Children
A Study of MK-2060 in Healthy Participants (MK-2060-016)
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
PeriOperative ISchemic Evaluation-3 Trial